Safety and Food-Effect Study of ABBV-CLS-7262 in Healthy Volunteers

Phase 1, randomised, open-label trial of fosigotifator in leukoencephalopathy with vanishing white matter (VWM) and amyotrophic lateral sclerosis (ALS), sponsored by Calico Life Sciences. Primary endpoints: Pharmacokinetics (AUC, Cmax) with or without food at 2 weeks and Pharmacokinetics (AUC, Cmax) with or without applesauce at 2 weeks. Started Dec 2023; status: completed.